

RESEARCH

Open Access



Intensity-dependent gamma electrical stimulation regulates microglial activation, reduces beta-amyloid load, and facilitates memory in a mouse model of Alzheimer's disease

Qian Liu^{1,5}, Adam Contreras¹, Muhammad Shan Afaq¹, Weijian Yang², Daniel K. Hsu¹, Michael Russell¹, Bruce Lyeth³, Theodore P. Zanto^{4*} and Min Zhao^{1*} 

Abstract

Background Gamma sensory stimulation may reduce AD-specific pathology. Yet, the efficacy of alternating electrical current stimulation in animal models of AD is unknown, and prior research has not addressed intensity-dependent effects.

Methods The intensity-dependent effect of gamma electrical stimulation (GES) with a sinusoidal alternating current at 40 Hz on A β clearance and microglia modulation were assessed in 5xFAD mouse hippocampus and cortex, as well as the behavioral performance of the animals with the Morris Water Maze.

Results One hour of epidural GES delivered over a month significantly (1) reduced A β load in the AD brain, (2) increased microglia cell counts, decreased cell body size, increased length of cellular processes of the Iba1 + cells, and (3) improved behavioral performance (learning & memory). All these effects were most pronounced when a higher stimulation current was applied.

Conclusion The efficacy of GES on the reduction of AD pathology and the intensity-dependent feature provide guidance for the development of this promising therapeutic approach.

Keywords Alternating current stimulation, Gamma wave, Alzheimer's disease, Microglia, Beta amyloid, A β , Learning and memory, 5xFAD mouse

*Correspondence:

Theodore P. Zanto
Theodore.Zanto@ucsf.edu
Min Zhao
minzhao@ucdavis.edu

¹Institute for Regenerative Cures, Department of Ophthalmology & Vision Science, Department of Dermatology, University of California Davis, Sacramento, CA 95817, USA

²Department of Electrical and Computer Engineering, University of California, Davis, CA 95616, USA

³Department of Neurological Surgery, University of California, Davis, CA 95616, USA

⁴Neuroscape, Department of Neurology, University of California San Francisco, San Francisco, CA 94158, USA

⁵Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder causing 60–70% of cases of dementia. As the disease advances, there is a gradual loss of gray and white matter, deficient memory, and other cognitive dysfunction, and the disease ultimately leads to death [1, 2]. Among the aging population, AD represents one of the most significant, and ever-increasing morbidity in the US and around the world. Currently, there are 5.5 million Americans with AD and by the year 2050, the population of adults aged 65+ is expected to nearly double, and those afflicted with AD are expected to quadruple. The medical and related care costs in the US are estimated to be \$236 billion, and projected to be more than \$1 trillion by 2050 [3, 4]. In response to this public health crisis, extensive research has been aiming to remediate AD pathology.

A popular target for therapeutics has been beta-amyloid ($A\beta$), which is necessary, though not sufficient, for the pathogenesis of AD [5]. The amyloid cascade hypothesis of AD postulates that $A\beta$ accumulation plays an important role in a chain reaction of events that leads to neuronal cell dysfunction and cell death, which gives rise to cognitive decline inherent to AD [6]. As such, numerous clinical trials have tested various pharmaceutical approaches toward remediating cognitive decline in AD by targeting $A\beta$ load. Unfortunately, despite reductions in $A\beta$ load, no pharmaceutical to date that targets $A\beta$, especially for the most toxic type for neuronal cells, $A\beta_{42}$, has demonstrated efficacy in concurrently remediating cognition [7].

On the other hand, clinical electroencephalography (EEG) has revealed an association of AD with the increased power of low-frequency oscillations, and a decreased power of higher-frequency oscillations, i.e., gamma (30–60 Hz) [8, 9]. Research has suggested that gamma-band oscillations (30–100 Hz) play an important role as a primary stimulus among nerve cells and higher information processing in the brain [8]. A recent breakthrough has demonstrated that 40-Hz (gamma wave frequency) stimulation may offer a promising therapeutic approach to reduce AD-specific pathology and improve performance in behaviors in animal models of AD [10–14]. Interestingly, gamma stimulation of several different methods in animal models of AD has demonstrated efficacy, including optogenetic stimulation, visual/audiovisual sensory stimulation, or magnetic stimulation. Here, we attempt to extend this work to the electrical domain by applying sinusoidal alternating current stimulation within the gamma band (at 40 Hz). Moreover, previous assessments of gamma stimulation have not addressed potential intensity-specific effects. Therefore, this study will assess the intensity-specific efficacy of gamma electrical stimulation (GES), because proper intensity-based

dosing is critical to the development of any therapeutic approach.

Electrical stimulation has been widely claimed to modulate brain function in humans [15, 16]. Most excitingly, GES in humans has recently been shown to significantly improve memory performances, along with restoration of intracortical connectivity measures of cholinergic neurotransmission, increased cortical blood perfusion, and possible reductions of tau [17–20]. Yet, the mechanisms of action rely on animal studies utilizing other forms of gamma stimulation. Here, we sought to fill this knowledge gap to address whether electrical stimulation similarly alters AD-specific pathology as other forms of gamma stimulation. Importantly, we will also assess fundamental unanswered questions regarding the intensity-specific (dose-response) effects of GES.

If GES has the same or similar effects on brain pathology and behavior performance in AD models, it will provide another powerful and practical modality to modulate gamma activities of the brain in patients. To test this, we established an epidural stimulation method guided by simulation of the electric field (EF) distribution within the brain. Here, we examined the effects of 40 Hz GES over a month in a 5xFAD mouse model of AD on $A\beta$ loading, microglia morphology, and behavioral (memory) performance. Results demonstrated that biomarkers associated with AD pathology in both the hippocampus and cortex were significantly reduced and memory performance was significantly improved in an intensity-specific manner.

Methods

Animals and Alzheimer's disease mouse model

This study was carried out following Animal Protocols #19,772 and #21,547 approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis. The mice were housed in a temperature-controlled environment (22 ± 0.5 °C) with a 12-hour-light-dark cycle and allowed free access to food and water. All efforts were made to ensure animal comfort and to reduce the number of animals used. We used 5xFAD mice as the Alzheimer's disease model for the GES treatment in this study. The 5xFAD mice at the age of 3 months were divided into five groups: (1) sham, $n=6$ mice; (2) 25 μ A at 40 Hz ($n=8$ mice); (3) 50 μ A at 40 Hz ($n=8$ mice); (4) 100 μ A at 40 Hz ($n=6$ mice); (5) 200 μ A at 40 Hz ($n=7$ mice). The 5xFAD transgenic mice (B6.Cg-Tg (APP^{SwFLon}, PSEN1^{*M146L}* L286V) 6799Vas/Mmjax) were purchased from the Jackson Laboratory (RRID: MMRRC_034848-JAX). As described previously [21], the 5xFAD strain overexpresses both mutant human amyloid beta (A4) precursor protein 695 (APP) with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimer's Disease (FAD) mutations

and human presenilin 1 (PS1) harboring two FAD mutations, M146L and L286V. 5xFAD transgenic mice recapitulate major features of Alzheimer's Disease amyloid pathology and may be useful models of intraneuronal A β 42 induced neurodegeneration and amyloid plaque formation. 5xFAD mice generate A β 42 almost exclusively, rapidly accumulating high cerebral levels. On this mixed C57BL/6 and SJL background (MMRRC stock 34,840), intraneuronal A β 42 accumulation is observed starting at 1.5 months of age, just before amyloid deposition, and gliosis, which begins at two months of age.

Electrode implanting surgery

The electrode implanting surgery was performed on all 5xFAD mice from each of the five experimental groups 24 h before the first GES session. As described previously [21], the mice received anesthesia with 2% (v/v) isoflurane in oxygen (0.2–0.5 L/min) before surgery. The animal was then mounted on a stereotactic apparatus and received a small (5–8 mm) scalp incision followed by two burr holes with a diameter of 1.5 mm, using a dental drill, at the coordinates: Anterior-Posterior (AP) = -2 mm, and Medial-Lateral (ML) = 4 mm left for one electrode and 4 mm right for the other electrode, relative to the bregma. Two stainless steel screws (0–80, DIA: 0.06 inch) were sterilized and implanted into the burr holes as electrodes (Fig. 1A–D). The electrodes were implanted to a depth of 0.5–0.8 mm from the bone surface, only touching, but not penetrating the dura (Fig. 1C). After the implantation, the electrodes were fixed with dental cement. During the entire surgery, the mouse was placed on a thermostatically controlled warming pad, and body temperature was monitored with a rectal thermometer. The depth of anesthesia was monitored every 10 min by a toe pinch to elicit a foot withdrawal. For the analgesic regimen, the mice received subcutaneous Carprofen at 2 mg/kg at the time of surgery. The mice were assessed twice daily in the following two days after the surgery, and Carprofen (2 mg/kg) was administered if the mice showed signs of pain or stress.

Mouse brain modeling and the FEM simulation

To assess the coverage and strength of GES to brain regions within the 5xFAD mice, such as the cortex and hippocampus, we applied the finite element method (FEM) to estimate the derived electric field (EF) distribution and intensity in a three-dimensional mouse brain model (Fig. 1E and G). We built the mouse brain model as reported previously [21], based on a 3D C57BL/6 mouse brain atlas built from MRI and Nissl histology, which consists of 39 different brain regions (Fig. 1E F) [22]. The regions were grouped as dura, arachnoid, grey matter, white matter, or cerebral ventricles, and assigned the relative electrical conductivity and relative

permittivity (at 40 Hz, stimulation frequency used in the study) [23]. The defined 3D model was then rendered, so it contains a total of $107 \times 152 \times 105$ voxels with voxel resolutions $\sim 100 \times 100 \times 100 \mu\text{m}^3$. Modeled electrodes were placed over the dura through a craniotomy hole (Fig. 1E F, in red and blue). We used the Sim4Life platform (v4.4.2.3851, Zurich MedTech AG) to perform a quasi-electrostatic FEM simulation to calculate the derived EF distribution and intensity in the brain model (Fig. 1G).

Gamma electrical stimulation

GES was administrated through the implanted electrodes 24 h after the surgery. Before GES treatment, the 5xFAD mice were anesthetized with ketamine/xylazine (90/4.5 mg/kg, i.p.). The GES stimulating program was set as 40 Hz at 25 μA (n=8 mice), 50 μA (n=8 mice), 100 μA (n=6 mice), and 200 μA (n=7 mice). Stimulation was applied 1 h/day, on every other day of the 1st week; no stimulation in the 2nd week; for 1 h on Monday of the 3rd week; 1 h/day, on Monday and Sunday in the 4th week (Fig. 1H). For the Sham group (n=6), the mice received electrode implantation and anesthesia during the 4-week treatment duration, but with no GES. For the 4-week GES treatment, the body weight and neurological behavior were monitored once each day to assess the safety of GES on 5xFAD, as described previously [21]. After the programmed 4-week GES treatment, the mice were euthanized with overdosed CO₂. Cardiac perfusion with ice-cold 0.1 M phosphate buffer (PB) solution was performed to collect the brain tissue. Both hemispheres of the collected sham and GES-treated 5xFAD mouse brains were then separated in ice-cold 0.1 M PB solution. The left hemispheres were used for ELISA, and the right hemispheres were fixed in ice-cold 4% paraformaldehyde (PFA) for the following immunofluorescence analyses.

Enzyme-linked immunosorbent assay (ELISA)

The collected left hemispheres of 5xFAD mouse brains were dissected within an ice-cold 0.1 M PB solution. The hippocampus and cortex were separately collected in pyrogen/endotoxin-free tubes, for ELISA of A β 42 and A β 40. When analyzing samples, ~ 100 mg of the hippocampus or cortex was weighted. The tissue was then added into 800 μL 5 M guanidine-HCl (G4505-100G, Sigma-Aldrich, MO, USA)/50 mM Tris (T1378, Sigma-Aldrich, MO, USA) solution, pH 8.0, containing the Protease Inhibitor Cocktail and AEBSF (P2714-1BTL, Sigma-Aldrich, MO, USA). The mixture was then respectively homogenized at room temperature for 3.5 h. The homogenate was then diluted with a ten-fold volume ice-cold 0.1 M PB solution containing protease inhibitor cocktail, and centrifuged at 16,000 g for 20 min, at 4 °C. The supernatant was then harvested for ELISA of A β 42/A β 40 using the Mouse A β 42 ELISA Kit (KMB3441-96




Fig. 1 Intracranial GES for 5xFAD mouse and the FEM simulation analysis

A-C. Electrode implantation. Two stainless steel screws were implanted as the paired electrodes to deliver the intracranial sinusoidal alternating current stimulation (A), as shown in the skull at: Anterior-Posterior (AP) = -2 mm, and Medial-Lateral (ML) = 4 mm (left and right) to the bregma (B-C). The electrodes were screwed and immobilized in the skull with the distal end reaching the dura. The positioning of the electrodes was determined following computer simulation that indicates maximal electric fields/currents to the targeted regions – cortex and hippocampus [15]

D. A mouse with electrodes implanted. Following the implantation surgery, the animals were checked twice daily to ensure no infection, no changes in health and behaviors, and normal activities until the end of the experiment

E-F. Three-dimensional (3D) simulation of the distribution of electric fields in a mouse brain, based on C57BL/6 mouse brain atlas with MRI and Nissl histology, with 39 regions represented (in different colors). The simulation helped to determine the positioning of the electrodes (in red and blue) to achieve desired field distribution as in G

G. The Finite element method (FEM) simulation suggests electric field (EF) distribution in the brain, which would effectively stimulate the cortex (with EF intensity at ~ 100–150 mV/mm) and hippocampus (with EF intensity at ~ 10–80 mV/mm), two main regions affected by A β overload in AD.

H. Behavior tests (blue bars) and Gamma Electric Stimulation (GES, red bars). The 5xFAD mice (3-month-old, male) were randomly assigned into sham, Low-current, and High-current groups. Before the GES, the Morris Water Maze assessment consisted of training and probe trials performed in Week 0 (blue bar). The electrodes were implanted 24 h before the first stimulation. The stimulation was delivered (red bars) for 1 h each day on Monday, Wednesday, Friday, and Sunday of Week 1; for 1 h on Monday of Week 3 and 4, and then for 1 h on Sunday of Week 4, followed by immediate euthanization and brain tissue collection. The GES details were: 40 Hz at 25 μ A (n=8), 50 μ A (n=8), 100 μ A (n=6), and 200 μ A (n=7) (amplitudes produced and monitored by the Neuroelectronics® Starstim®). The sham mice (n=6) underwent every procedure, except that GES was not switched on. The Morris Water Maze test was performed in Week 4 (blue bar) as the learning and memory behavior assessment after the 4-week GES respectively

tests, Invitrogen) or the Mouse A β 40 ELISA Kit (KMB3481-96 tests, Invitrogen), following the manufacturer's instruction. After the anti-A β 42, IgG HRP, and chromogen incubations, the 96-well plate was placed in a Microplate Spectrophotometer (BioTek, US) to read the absorbance at 450 nm. The concentrations of the samples were read from the stand curve, generated according to the A β 42 standard.

Immunofluorescence

The collected right hemispheres of 5xFAD mouse brains were used for immunofluorescence of NeuN/A β 42, NeuN/A β 40, and Iba1/A β 42. The hemisphere samples were fixed in ice-cold 4% PFA at 4 °C for 3 days, and transferred into a 30% (v/v) sucrose solution at 4 °C for tissue dehydration for 3 days. Afterward, the hemispheres were respectively frozen and coronally sectioned at 40 μ m intervals with a cryostat microtome. To detect protein expressions in the hippocampus and cortex, specific hemisphere sections were collected following

the previous description [21, 24, 25]: coronal sections between AP: -1.2 mm and -2.7 mm (1.5 mm in thickness) from the bregma.

The 40 μm hemisphere slices were then further fixed in 4% PFA for 30 min and permeabilized in 0.1% Triton X-100 (T8787, Sigma-Aldrich, MO, USA) for 30 min. The slices were then incubated in 3% bovine serum album (BSA) in 0.1 M phosphate-buffered saline (PBS) solution at room temperature for 1 h. After the non-specific protein blocking, the slices were incubated with diluted primary antibodies: anti-NeuN (1:1000, MAB377, Sigma-Aldrich, MO, USA), anti-A β 42 (1:1000, #805,501, BioLegend), anti-A β 40 (1:1000, #805,401, BioLegend) and anti-Iba1 (1:1000, #019-19741, FUJIFILM Wako Chemicals USA) at 4° C, overnight. The slices were then rinsed with 0.1 M PB solution three times at room temperature and incubated with diluted goat anti-mouse/rabbit (Alex Fluor 594/488, 1:1000, #A-11,005, #A-11,034, Invitrogen) secondary antibodies. ProLong Gold Antifade Mountant with DAPI (P36931, Invitrogen) was used to label nuclei and fix the final slice for fluorescence detection with confocal laser-scanning microscopy (Leica SP8 STED 3X microscope with 20X and 63 \times 1.4 NA objectives).

Quantification of immunopositive cells

As previously published [21], the Iba1 immunopositive cell counting, cell body diameter, and process measurements in the hippocampus and cortex were performed with ImageJ software. Specifically, we used a stereological method to obtain coronal brain sections at 40 μm intervals for immunofluorescence. We used 20X and 10X objectives to identify Iba1+ cells at 5 section intervals (200 μm apart), and within each section, we selected 3 fields of view from an area of 200 \times 200 μm^2 for cell counting. We calculated cell counts and measurements for the hippocampal and cortical regions in each animal and then averaged them to obtain group means and standard errors of the mean (SEM), following the systematic random sampling protocol of stereology [26, 27]. We have used this method in our previous research publications, particularly in studies involving the DG region of the hippocampus [21, 24, 25]. The DG region of a mouse can be easily detected in almost full view under the 20X and 10X confocal microscope in three snapshots in the coronal plane. Therefore, the DG region was not manually selected, but captured in its entirety. In the sagittal plane, we collected data from almost all sections to ensure that we did not miss any stereological cell count data. The cell counts and measurements in the hippocampal and cortex regions of each animal were calculated and averaged to obtain the group means and standard error of the mean (SEM).

The morris water maze (MWM)

The MWM consisted of a 4-day training session and a 60-second assessment session on Day 5. For each training session, mice were placed into the pool at one of four semi-randomly chosen starting points and given 60 s to reach the platform. Any mouse that does not reach the platform within 60 s was led to the platform by the experimenter and allowed to remain on the platform for 10 s. Twenty-four hours after the final training session, mice were given an assessment session lasting 60 s, where the platform had been removed from the pool. Swim paths were recorded using a video tracking system. During training sessions, swim distance, latency to reach the platform, and swim speed were measured. During the assessment session, swim distance, swim speed, swim time in each quadrant, and the time spent in the platform zone were measured. Efficiency was calculated as the ratio of the direct distance from the start point to the hidden escape platform to the actual distance the mouse swam from the start point to the platform. To assess episodic memory, assessment data (day 6) was submitted to an ANOVA with Group (Sham, Low-current, high-current) and Session (pre-GES, post-GES) as factors. To assess learning, data from the training sessions were modeled across days, and slopes of best fit were submitted to the same ANOVA as before.

Statistics

Data analysis was performed using GraphPad Prism 8 (GraphPad Software, Inc., CA, US), which adheres to a general linear model. The alpha level for Type I error was set at 0.05 for rejecting null hypotheses. Data were expressed as mean \pm standard error of the mean (SEM). Microglia cell activation assessed from Iba1 staining was separately analyzed by one-way ANOVA for each group, followed by a Tukey's Honestly Significant Difference *post-hoc* analysis for the 5xFAD+sham and 5xFAD+GES group comparisons.

Results

GES decreased A β 42 and A β 40 load in the hippocampus and cortex of 5xFAD mice

The FEM simulation suggested that GES delivered from the electrodes as positioned effectively reached the cortex and the hippocampus. For example, GES of 40 Hz at 100 μA induced 10–80 mV/mm in the hippocampus (Fig. 2A) and ~100–150 mV/mm in the cortex (Fig. 2G). These regions were then assessed in the following analyses utilizing ELISA and immunofluorescence microscopy.

After the 4-week stimulation program (Fig. 1H), brain tissue was collected for A β 42 and A β 40 load detection (Fig. 2B H). Positioning of the electrodes was selected for effective delivery of electric stimulation to the cortex and the hippocampus of the mouse brain as previously




Fig. 2 GES decreased Aβ42 and Aβ40 in the hippocampus and cortex of 5xFAD mice

A, G. EF distribution to the hippocampus (**A**) and cortex (**G**) simulated by the FEM.

B, H. Following the 4-week GES, the hippocampus (**B**, red box) and cortex tissues (**H**, red box) of 5xFAD mice from each group were separately collected for Aβ42/ Aβ40 ELISA assay and immunofluorescence microscopy. **C-D, I-J.** ELISA assay showed that the GES treatment significantly decreased Aβ42 and Aβ40 concentrations in the hippocampus (**C-D**) and the cortex (**I-J**) following GES in 25, 50, 100, and 200 μA groups. **E-F, K-L.** Typical example immunofluorescence images show significantly decreased Aβ42 (red in **E** and **K**) and Aβ40 (red in **F** and **L**) labeling in the dentate gyrus (DG) of the hippocampus (**E-F**) and in the cortex (**K-L**) following 200 μA GES. NeuN (green) and DAPI (blue) were used to label neurons and nuclei. Scale bars: 50 μm

Data were presented as mean ± SEM. * P < 0.05, ** P < 0.01, and *** P < 0.001 were considered as significantly different for GES groups vs. sham

simulated and detailed [21]. The A β 42 and A β 40 concentrations from these two regions were subsequently quantified via an ELISA immunoassay and assessed with a one-way ANOVA to compare the GES groups and Sham. Results of the ANOVA exhibited a main effect (A β 42: $F(4, 28)=3.440$, $P=0.0208$, for the hippocampus; $F(4, 28)=14.32$, $P<0.0001$, for cortex; A β 40: $F(4, 28)=2.748$, $P=0.0480$, for the hippocampus; $F(4, 28)=3.386$, $P=0.0222$ for the cortex). The A β 42 concentration in sham 5xFAD mice was quantified as 101.0 ± 17.6 ng/mL in the hippocampus and 139.7 ± 11.5 ng/mL in the cortex (Sham). Compared to the Sham group, the A β 42 concentration in the 200 μ A GES group was significantly decreased to 41.2 ± 6.1 ng/mL ($P=0.0089$) in the hippocampus and 51.3 ± 11.1 ng/mL ($P<0.0001$) in the cortex. On the other hand, compared to the Sham group, the A β 40 concentration in the 200 μ A GES group showed no significant change in the hippocampus, but was significantly attenuated to 956.2 ± 230.0 ng/mL (1950.0 ± 230.4 in sham, $P<0.0001$) in the cortex (Fig. 2C, D and I J). To confirm the ELISA result, the A β 42 and A β 40 immunofluorescence was also performed. Visual inspection and quantification of the immunofluorescence data indicated that the sham 5xFAD brains loaded relatively more A β 42 and A β 40 in the hippocampus and cortex, while the A β 42 and A β 40 load was decreased in the 200 μ A GES treatment groups. (Figure 2E F and 2K-L).

GES-regulated microglial activation in the hippocampus of 5xFAD mice

As the immune cells in the brain, microglia serve as the main cell type to clear extra pathogens, including A β . To address the mechanism of A β clearance by GES, we further evaluated the regulation of microglial activation through the Iba1+cell counts, cell body diameters, and neurite processes [11, 28] in the same brain regions of the hippocampus and cortex. By visual inspection and quantification of the immunofluorescence and microglia morphology, the high-current intensity group demonstrated increased Iba1+cell counts, decreased cell body sizes, and prolonged neurite processes in both the hippocampus (Fig. 3A C) and cortex (Fig. 4A C). To quantify these observations, Iba1+cell counts were submitted to ANOVA and exhibited a main effect ($F(4, 30)=11.08$, $P<0.0001$, for hippocampus; $F(4, 30)=6.634$, $P=0.0006$, for cortex). In the sham 5xFAD mice, the Iba1+mean cell counts were detected at 97 ± 11 cells/mm² in the hippocampus (Fig. 3D) and 320 ± 47 cells/mm² in the cortex (Fig. 4D). Compared to the Sham group, the 100 and 200 μ A GES treatment groups exhibited a significant increase in the Iba1+cell counts in both the hippocampus (184 ± 25 cells/mm² in 100 μ A GES group, $P=0.01$; 207 ± 22 cells/mm² in 200 μ A GES group, $P=0.001$, Fig. 3D) and the cortex (634 ± 76 cells/mm² in 100 μ A

GES group, $P=0.006$; 672 ± 73 cells/mm² in 200 μ A GES group, $P=0.002$, Fig. 4D). Although the cell counts were also increased in the 25–50 μ A GES treatment groups, there was no significant difference compared to the Sham.

A similar effect of GES was observed on Iba1+cell body diameters ($F(4, 30)=8.351$, $P=0.0001$, for hippocampus; $F(4, 30)=2.956$, $P=0.0359$, for cortex). In the Sham 5xFAD mice, the mean cell body diameter was measured as 17.7 ± 1.3 μ m in the hippocampus (Fig. 3E) and 14.2 ± 1.0 μ m in the cortex (Fig. 4E). In the 200 μ A GES treatment group, the Iba1+mean cell body diameters in both brain regions were significantly decreased to 8.6 ± 1.2 μ m in the hippocampus ($P=0.0002$, Fig. 3E) and to 10.4 ± 0.7 μ m in the cortex ($P=0.0433$ Fig. 4E). Although the mean cell body diameters were also decreased in the 25–100 μ A GES treatment group, there was no significant difference compared to Sham.

Again, a similar effect was observed for mean lengths of Iba1+neurite processes ($F(4, 30)=13.04$, $P<0.0001$, for hippocampus; $F(4, 30)=5.020$, $P=0.0032$, for cortex). In the Sham 5xFAD mice, the mean length of neurite processes was measured as 12.5 ± 1.59 μ m in the hippocampus (Fig. 3F) and 11.7 ± 2.5 μ m in the cortex (Fig. 4F). In the 100 and 200 μ A GES treatment groups, the mean length of Iba1+cell neurite processes in both brain regions was significantly increased in the hippocampus (23.3 ± 2.3 μ m in 100 μ A GES group, $P=0.003$; 25.1 ± 1.9 μ m in 200 μ A GES group, $P=0.0005$, Fig. 3F) and the cortex (20.8 ± 1.4 μ m in 100 μ A GES group, $P=0.009$; 20.4 ± 2.0 μ m in 200 μ A GES group, $P=0.017$, Fig. 4F). Although the process lengths were also increased in the 25–50 μ A GES treatment groups, no significant difference was observed compared to the Sham. In summary, the Iba1+microglial activation in the hippocampus and cortex of 5xFAD mice was regulated significantly by the 40 Hz gamma GES when applied with a ~200 μ A current intensity, but not with a 25–100 μ A current intensity.

GES enhanced memory function in 5xFAD mice

To assess the effect of GES on the cognitive functions of 5xFAD mice, we performed the MWM assessment [29]. The MWM included two stages of training, and assessment trials to separately measure learning (swimming to find the invisible escaping platform under the water, Training Day 1–4) and memory (on Day 5, the platform was removed, and swimming around the platform area) functions. Learning was assessed and analyzed by 5xFAD mouse swimming efficiency and latency time towards the invisible escape platform in the 4-day training trial of the MWM, before (Week 0) and after (Week 4) the 4-week GES treatment (Fig. 1H). Memory was assessed and analyzed with the time percentage spent at the target




Fig. 3 The GES modulated microglia activation in the hippocampus of 5xFAD mice. **(A)** EF distribution to the hippocampus simulated by the FEM. **(B)** The DG region of the hippocampus was assessed for microglia activation modulation. **(C)** The 4-week GES modulated Iba1+ (green) cell activation in DG of 5xFAD mice. The morphological characteristics of microglia were analyzed for the number of Iba1+ cells, cell body size and length, and number of processes from Iba1+ cells. Along with the Iba1+ microglia activation, the reduction of Aβ42 (red) labeling was also detected. DAPI was used as a nuclear counterstain. Scale bars as shown. **(D)** The GES significantly increased the cell count of Iba1+ microglia in 100 and 200 μA groups than that in the sham group. **(E)** The GES significantly decreased the average cell body diameter of Iba1+ microglia in 100 and 200 μA groups than that in the sham group. **(F)** The GES significantly increased the numbers of the average Iba1+ processes in DG of 100 and 200 μA groups than that in the sham group. Data are mean ± SEM from the sham (n=6 mice), 25 μA (n=8), 50 μA (n=8), 100 μA (n=6), and 200 μA (n=7) groups. *P < 0.05, **P < 0.01, and *** P < 0.001 were considered significantly different for GES groups vs. sham




Fig. 4 The GES modulated microglia activation in the cortex of 5xFAD mice. **(A)** EF distribution to the hippocampus simulated by the FEM. **(B)** The cortex region was assessed for microglia activation modulation. **(C)** The GES modulated Iba1+ (green) cell activation in the cortex. The morphological characteristics of microglia activation were analyzed for changes in cell body size, extension, and number of cell processes. Along with the Iba1 + microglia activation, the reduction of Aβ42 (red) labeling was also detected. DAPI was used as a nuclear counterstain. Scale bars as shown. **(D)** The GES significantly increased the cell count of Iba1 + microglia in 100 and 200 μA groups than that in the sham group. **(E)** The GES significantly decreased the average cell body diameter of Iba1 + microglia in 50, 100, and 200 μA groups than that in the sham group. **(F)** The GES significantly increased the numbers of the average Iba1 + process in DG of 100 and 200 μA groups than that in the sham group. Data are mean ± SEM from the sham (n=6 mice), 25 μA (n=8), 50 μA (n=8), 100 μA (n=6), and 200 μA (n=7) groups. *P < 0.05, **P < 0.01, and *** P < 0.001 were considered significantly different for GES groups vs. sham

quadrant in a 60-second assessment trial of the MWM, before (Week 0) and after the 4-week GES treatment (Fig. 1H).

Assessment of the training data showed improved learning following the 25–200 μA GES treatment, as

indicated by swimming efficiency (Fig. 5A and E) and the latency (time in seconds) to the hidden platform (Fig. 5F J). However, the sham 5xFAD mice showed no swimming efficiency improvement or latency decrease. The results suggest that the one-month GES treatment significantly




Fig. 5 The GES enhanced learning and memory performance of 5xHAD mice. The Morris Water Maze test was carried out as detailed in Materials and Methods (Fig. 1) for swimming efficiency and latency to the invisible escape platform in a 4-day training trial before (Wk 0) and after (Wk 4). The memory enhancement was assessed with the time percentage spent at the target quadrant (at which quadrant the platform was removed) in a 60-second probe trial, before and after GES. **A-E**. The swimming efficiency was enhanced in 25–200 μ A GES groups. **F-J**. The latency to find the hidden platform was attenuated in 25–200 μ A GES groups. **K**. The percentage time in the target quadrant of probe trials showed significantly improved memory in the 200 μ A GES group. **L**. Representative swimming paths before and after the 4-week GES treatment. Data are mean \pm SEM from 200 μ A group ($n=7$ mice), 50 μ A group ($n=8$), and sham group ($n=6$ mice). Data are mean \pm SEM from the sham ($n=6$ mice), 25 μ A ($n=8$), 50 μ A ($n=8$), 100 μ A ($n=6$), and 200 μ A ($n=7$) groups. * $P < 0.05$ was considered as significantly different for after vs. before GES

enhanced the learning function of the 5xHAD mice, and the 200 μ A GES treatment was more beneficial than those with the lower current intensity.

Assessment of memory, as indexed by the assessment data (Fig. 5K L), showed that the sham 5xHAD mice exhibited no significant improvement in swimming in the Target quadrant from Week 0 to 4 (from $23.8 \pm 2.6\%$ to $29.9 \pm 6.5\%$, $P=0.4069$). On the other hand, swimming time in the target quadrant improved from Before (Week 0) to After (Week 4) GES in the 200 μ A GES treated 5xHAD mice (from $24.8 \pm 3.7\%$ at Week 0 to $42.8 \pm 5.4\%$ at Week 4, $P=0.0396$, Fig. 5K L). However, there was no significance detected in the 25, 50, and 100 μ A GES groups. The results demonstrated significantly improved memory

performance in the 200 μ A GES treatment groups of 5xHAD mice.

Discussion

In this study, we assessed the effects of GES on biomarkers and behavioral performance measures affected by AD pathology. Compared to a sham control group, one month of GES treatment resulted in lower A β 42 load in the hippocampus and cortex as well as improved learning and memory performance. Interestingly, these effects were most pronounced in the group that received high-current GES at 100–200 μ A. Moreover, the 100–200 μ A GES treatment group also exhibited enhanced microglia characteristics, including increased cell counts, smaller cell-body diameters, and longer cell processes. Together,

these results highlight the utility of GES as a potential therapeutic intervention to slow or remediate AD pathology.

Electrical activities of the brain that oscillate at 30–100 Hz are grouped as Gamma waves, which have been demonstrated to be involved in neurocircuit function, behavior, and memory [13, 30]. Importantly, multicenter research provides strong evidence suggesting that patients with Alzheimer's Dementia have decreased Gamma activities [31, 32]. Similarly, in experimental animal models, 5XFAD mice have reduced measures in gamma activities [11]. It is therefore interesting that applying stimulation at this deficient frequency (gamma) can have a positive effect on AD pathology and symptoms.

Various types of brain stimulation to induce gamma oscillations have been investigated for their effects on brain pathology, learning, and memory functions. Those include magnetic, sensory, and optogenetic forms of gamma stimulation. Exciting results from those elegant experiments in animal models of AD have demonstrated improved memory, lowered tau and A β load, increased hippocampal long-term potentiation and vascular dilation, and can change activation responses in microglia and astrocytes [10–14].

In contrast, a recent study using multisite silicon probe recording in the cortex and hippocampus found that 40 Hz optical flicker stimulation did not induce native gamma oscillations in these regions. In addition, they found no reliable changes in A β plaque levels or microglial activation by either immunohistochemistry or in vivo two-photon imaging following the flicker stimulation [33]. The results suggest that optical flicker stimulation may not be a very consistent mechanism nor a method for modulating effectively the neuro-network activity and AD brain pathology.

Whereas, electrical stimulation (intracranial or intra-brain) can directly deliver the 40 Hz electrical signal to neural networks without the involvement of visual or audio sensory mechanisms. Electrical stimulation perhaps can minimize sensory adaptation and avoidance behavior of the animals. Importantly, one of our previous intra-brain electric stimulation studies to guide the migration of neural stem cells in vivo yielded a significant increase in gamma oscillation, but not the theta and beta (please see Fig. S5, panel E. in [34]. That particular result was NOT an intended goal of the original study [34], thus electric stimulation perhaps could be regarded as a more consistent approach to entrain gamma waves. The potential differences between sensory entrainment and direct electrical entrainment will be a future research topic for rescuing the gamma oscillation in various network models considering the conflicting results from sensory inputs [10–14, 33].

Here, we extend these results to the electrical domain to show that GES can lower A β 42, enhance microglia characteristics, and improve learning and memory. These results converge with our previous report that GES can facilitate neurogenesis [21]. Thus, GES appears to exhibit similar efficacy as the other forms of gamma stimulation. Moreover, these results provide key mechanistic insights as to why GES has exhibited initial efficacy in human trials [17–20].

We also provided novel evidence that GES is intensity-dependent, such that a higher electrical current yielded more pronounced effects. This finding is a critical first step toward understanding the dose-response relationship of this potential therapeutic. The question remains as to what intensity, and for what duration, is optimal for therapeutic use – and how that dose-response curve may differ across the different gamma stimulation techniques.

Precision electrical stimulation of brain structures can be achieved through stereotactic implantation of fine electrodes, which have been well-developed for humans and experimental animals [34, 35]. Stereotaxic brain electrode implantation has been successfully used for various diseases [35–43]. However, complications do happen despite significantly expensive and surgically-demanding procedures [44, 45]. On the other hand, non-invasive stimulation from electrodes on the scalp suffers from poor targeting, and uncertainty of where electric currents would flow and how electric fields may build are not well studied and remain unclear. It is estimated that over 75% of the electrical current from scalp electrodes is attenuated by soft tissue and the skull [46, 47]. Here, using an MRI image-based technique, we were able to simulate the plausibility of using electrodes implanted in the skull and epidural (non-invasive to the brain) to stimulate intracerebral structures. We used a finite element method (FEM) to estimate the distribution of current and applied electric field in a three-dimensional brain model [21–23, 46, 48, 49]. Multiple simulations of the current/field were calculated using electrodes placed at different positions in order to identify electrode positions that would maximally stimulate the cortex and hippocampus. This approach, therefore, permitted an optimal solution for electrode positioning and enabled the targeting of specific structures for stimulation and subsequent tissue analysis via ELISA and immunofluorescence microscopy. GES delivered in such a way indeed has significant effects on brain pathology and animal behaviors, with minimal invasiveness. Indeed, observation of the animal behaviors, and anatomy, and through the histological examination of the brain did not show any detrimental effects from the epidural stimulation procedure.

Microglial activation provides the first line of defense in amyloid plaque clearance whenever injury or disease occurs, including in AD [50–54]. In the early stages of

AD, microglia play a beneficial role in reducing A β accumulation [55, 56] and can facilitate learning and memory by promoting learning-related synapse formation [57], which helps delay the progression of AD. However, in later stages of AD, persistent microglial activation by amyloid plaques results in a shift from neuroprotective to neurotoxic microglial phenotypes that produce pro-inflammatory cytokines, which in turn can increase A β production, neural damage, and are related to tau-mediated neurodegeneration [58, 59]. A recent study reported microglial activation and clustering around amyloid plaques by visual gamma stimulation in Alzheimer's model mouse brain [11]. Indeed, recent studies have reported microglial activation clustering around amyloid plaques as well as improved memory by auditory and visual gamma stimulation in an Alzheimer's model mouse brain [10, 11]. This supports the notion that microglial activation may underlie known GES effects on A β load and memory performance. Yet, additional research is needed to elucidate the effect of GES on microglial activation as a potential mechanism of A β load reduction and improved memory in the AD brain. Moreover, it remains unclear why such a narrow frequency (40 Hz) exhibits efficacy, but not harmonic (80 Hz) or subharmonic (20 Hz) frequencies [11] and whether such frequency specificity would be observed across the different forms of gamma stimulation. There are indeed many critical biological processes, including cell migration, cell proliferation, and cell differentiation that are associated with oscillatory cell signaling [60–66]. Therefore, future research will need to address the mechanisms that underlie frequency specificity. There is a possibility that the electrical stimulation used in our experiments could affect the motor cortex, which might in turn result in more efficient swimming behavior after GES. This can not be excluded nor confirmed in our study. The memory effects are at least independent of the effects on the motor cortex. We are developing more localized stimulation strategies, which will help to determine the effects of stimulation on more specific brain regions.

Conclusion

In this study, we provided a FEM modeling approach to estimate to which brain parts intracranial electrical stimulation are likely to deliver the electric signal. Importantly, it demonstrated the feasibility of targeting the cortex and hippocampus. The results demonstrated the decreased A β load and regulated microglia activation in the hippocampus and cortex of the 5xFAD mice by GES with a sinusoidal alternating current at 40 Hz. With the four-week GES trial, the learning and memory performance was significantly improved in the 5xFAD mice. Furthermore, the GES-induced effects were identified in a current intensity-dependency manner. As

similar approaches are under trials in humans to facilitate memory function, our research, therefore, will have direct clinical relevance and significance, which currently affects ~5.5 million Americans and many more worldwide.

Abbreviations

AD	Alzheimer's disease
5xFAD	The five-familial Alzheimer's Disease transgenic mouse
EF	electric field
GES	Gamma electrical stimulation
FEM	finite element method
CSF	cerebral spinal fluid
AP	Anterior-Posterior
ML	Medial-Lateral
MWM	Morris Water Maze
PFA	paraformaldehyde
PBS	phosphate-buffered saline
DAPI	4',6-diamidino-2-phenylindole

Acknowledgements

The authors would like to thank Dr. Ingrid Brust-Mascher for assistance with confocal microscopy.

Author contributions

QL, TZ, and MZ developed the conception and designed the study. QL carried out the experiments and data analysis with the assistance of MR, AC, and MA. WY contributed to mouse brain modeling and FEM simulation. BL participated in data interpretation. QL, MZ, and TZ wrote the first draft of the manuscript. All authors contributed to the drafting and editing of the manuscript. All authors approved the final manuscript.

Funding

This work was funded by the National Institute on Aging grant R21AG060335. The research in the Zhao Laboratory at UC Davis is supported by an AFOSR MURI grant (FA9550-16-1-0052, Program Leader: Wolfgang Losert, University of Maryland), NIH 1R01EY019101, and a DARPA grant (D20AC00003, Program Leader: Marco Rolando, University of California Santa Cruz).

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding authors upon reasonable request.

Declarations

Ethics approval and consent to participate

The animal surgery and stimulation were performed in compliance with all international and NIH guidelines for the care and use of laboratory animals, in accordance with the University of California, Davis, Institutional Animal Care and Use Committee guidelines.

Consent for publication

Not applicable.

Competing interests

MZ is an inventor of - U.S. Patent US 9044611 B2; 11,634,702. The other authors declare that they have no competing interests.

Received: 21 February 2023 / Accepted: 14 July 2023

Published online: 28 July 2023

References

- Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. *N Engl J Med*. 1995;333(19):1242–7.

2. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. *Neurobiol Aging*. 2005;26(3):383–9.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. *Alzheimers Dement*. 2007;3(3):186–91.
4. PH. Paul Howard, *Unlocking Precision Medicine*, Encounter Books (2016).
5. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME, Brickman AM. Alzheimer's Disease Neuroimaging, White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? *JAMA Neurol*. 2013;70(4):455–61.
6. Jack CR Jr, Knopman DS, Jagster WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119–28.
7. Amanatkar HR, Papagiannopoulos B, Grossberg GT. Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. *Expert Rev Neurother*. 2017;17(1):7–16.
8. McDermott B, Porter E, Hughes D, McGinley B, Lang M, O'Halloran M, Jones M. Gamma Band neural stimulation in humans and the Promise of a New Modality to prevent and treat Alzheimer's Disease. *J Alzheimers Dis*. 2018;65(2):363–92.
9. Cassani R, Estarellas M, San-Martin R, Fraga FJ, Falk TH. Systematic review on resting-state EEG for Alzheimer's Disease diagnosis and Progression Assessment. *Dis Markers*. 2018;2018:5174815.
10. Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory Gamma Stimulation ameliorates Alzheimer's-Associated Pathology and improves cognition. *Cell*. 2019;177(2):256–271.e22.
11. Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature*. 2016;540(7632):230–5.
12. Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma Entrainment binds higher-order brain regions and offers neuroprotection. *Neuron*. 2019;102(5):929–943.e8.
13. Adaikkan C, Tsai LH. Gamma Entrainment: impact on neurocircuits, Glia, and Therapeutic Opportunities. *Trends Neurosci*. 2020;43(1):24–41.
14. Zhen J, Qian Y, Weng X, Su W, Zhang J, Cai L, Dong L, An H, Su R, Wang J, Zheng Y, Wang X. Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease. *Alzheimers Dement (NY)*. 2017;3(4):487–97.
15. Herrmann CS, Rach S, Neuling T, Struber D. Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. *Front Hum Neurosci*. 2013;7:279.
16. Zhao H, Qiao L, Fan D, Zhang S, Turel O, Li Y, Li J, Xue G, Chen A, He Q. Modulation of brain activity with Noninvasive Transcranial Direct Current Stimulation (tDCS): clinical applications and safety concerns. *Front Psychol*. 2017;8:685.
17. Benussi A, Cantoni V, Cotelli MS, Cotelli M, Brattini C, Datta A, Thomas C, Santarnecchi E, Pascual-Leone A, Borroni B. Exposure to gamma tACS in Alzheimer's disease: a randomized, double-blind, sham-controlled, crossover, pilot study. *Brain Stimul*. 2021;14(3):531–40.
18. Kehler L, Francisco CO, Uehara MA, Moussavi Z. The effect of transcranial alternating current stimulation (tACS) on cognitive function in older adults with dementia. *Annu Int Conf IEEE Eng Med Biol Soc*. 2020;2020:3649–53.
19. Sprugnoli G, Munsch F, Cappon D, Paciorek R, Macone J, Connor A, Fakhri GE, Salvador R, Ruffini G, Donohoe K, Shafi MM, Press D, Alsop DC, Pascual Leone A, Santarnecchi E. Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease. *Alzheimers Res Ther*. 2021;13(11):203.
20. Dhaynaut M, Cappon D, Paciorek R, Macone J, Connor A, Guehl NJ, Pascual-Leone A, Fakhri GE. E.J.T.J.o.N.M. Santarnecchi, Effects of modulating gamma oscillations via 40Hz transcranial alternating current stimulation (tACS) on tau PET imaging in mild to moderate Alzheimer's Disease. *J Nucl Med*. 2020;61:340.
21. Liu Q, Jiao Y, Yang W, Gao B, Hsu DK, Nolte J, Russell M, Lyeth B, Zanto TP, Zhao M. Intracranial alternating current stimulation facilitates neurogenesis in a mouse model of Alzheimer's disease. *Alzheimers Res Ther*. 2020;12(1):89.
22. Johnson GA, Badea A, Brandenburg J, Cofer G, Fubara B, Liu S, Nissanov J. Waxholm space: an image-based reference for coordinating mouse brain research. *NeuroImage*. 2010;53(2):365–72.
23. G. C. Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies, Report N.A.L/OE-TR- 1996-0037, Occupational and environmental health directorate, Radiofrequency Radiation Division, Brooks Air Force Base, Texas (USA). DOI:<https://doi.org/10.21236/ada303903> (1996).
24. Sorrells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, James D, Mayer S, Chang J, Auguste KI, Chang EF, Gutierrez AJ, Kriegstein AR, Mathern GW, Oldham MC, Huang EJ, Garcia-Verdugo JM, Yang Z. Alvarez-Buylla, human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. *Nature*. 2018;555(7696):377–81.
25. Sherafat MA, Heibatollahi M, Mongabadi S, Moradi F, Javan M, Ahmadiani A. Electromagnetic field stimulation potentiates endogenous myelin repair by recruiting subventricular neural stem cells in an experimental model of white matter demyelination. *J Mol Neurosci*. 2012;48(1):144–53.
26. Burke M, Zangenehpour S, Mouton PR, Prito M. Knowing what counts: unbiased stereology in the non-human primate brain. *J Vis Exp* (27) (2009).
27. Brugghe J, Baak JP, Meijer GA, van Diest PJ, Brinkhuis M. Rapid and reliable assessment of volume percentage of epithelium in borderline and invasive ovarian tumors. *Anal Quant Cytol Histol*. 1998;20(1):14–20.
28. Hovens I, Nyakas C, Schoemaker R. A novel method for evaluating microglial activation using ionized calcium-binding adaptor protein-1 staining: cell body to cell size ratio. *Neuroimmunol Neuroinflammation*. 2014;1:82–8.
29. Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer's disease model mice. *J Vis Exp* (53) (2011).
30. Buzsaki G, Anastassiou CA, Koch C. The origin of extracellular fields and currents—EEG, ECoG, LFP and spikes. *Nat Rev Neurosci*. 2012;13(6):407–20.
31. Smailovic U, Johansson C, Koenig T, Kareholt I, Graff C, Jelic V. Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer's Disease Patients-Relationship to APOE epsilon4. *Brain Sci* 11(10) (2021).
32. Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V. Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging*. 2005;26(2):165–71.
33. Soula M, Martin-Avila A, Zhang Y, Dingra A, Nitzan N, Sadowski MJ, Gan WB, Buzsaki G. Forty-hertz light stimulation does not entrain native gamma oscillations in Alzheimer's disease model mice. *Nat Neurosci*. 2023;26(4):570–8.
34. Feng JF, Liu J, Zhang L, Jiang JY, Russell M, Lyeth BG, Nolte JA, Zhao M. Electrical Guidance of Human Stem cells in the rat brain. *Stem Cell Reports*. 2017;9(1):177–89.
35. Kratimenos GP, Thomas DG, Shorvon SD, Fish DR. Stereotactic insertion of intracerebral electrodes in the investigation of epilepsy. *Br J Neurosurg*. 1993;7(1):45–52.
36. Wardell K, Zsigmond P, Richter J, Hemm S. Relationship between laser doppler signals and anatomy during deep brain stimulation electrode implantation toward the ventral intermediate nucleus and subthalamic nucleus, *Neurosurgery* 72(2 Suppl Operative) (2013) ons127–40; discussion ons140.
37. Satzer D, Lanctin D, Eberly LE, Abosch A. Variation in deep brain stimulation electrode impedance over years following electrode implantation. *Stereotact Funct Neurosurg*. 2014;92(2):94–102.
38. Sammartino F, Krishna V, King NK, Bruno V, Kalia S, Hodaie M, Marras C, Lozano AM, Fasano A. Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2016;87(8):859–63.
39. Pol S, Temel Y, Jahanshahi A. A Custom made Electrode Construct and Reliable Implantation Method that allows for long-term bilateral deep brain stimulation in mice. *Neuromodulation*. 2021;24(2):212–9.
40. Mazzone P, Stefani A, Viselli F, Scarnati E. Frameless Stereotaxis for Subthalamic Nucleus Deep Brain Stimulation: an innovative method for the direct visualization of Electrode Implantation by intraoperative X-ray control. *Brain Sci* 8(5) (2018).
41. DePaoli D, Goetz L, Gagnon D, Maranon G, Prud'homme M, Cantin L, Parent M, Cote DC. Intraoperative fiber optic guidance during chronic electrode implantation in deep brain stimulation neurosurgery: proof of concept in primates. *J Neurosurg*. 2019;132(6):1810–9.
42. Chapelle F, Manciet L, Pereira B, Sontheimer A, Coste J, El Ouadih Y, Cimpeanu R, Gouot D, Lapusta Y, Claise B, Sautou Y, Bouattour Y, Marques A, Wohrer A, Lemaire JJ. Early deformation of Deep Brain Stimulation Electrodes following Surgical Implantation: Intracranial, Brain, and Electrode mechanics. *Front Bioeng Biotechnol*. 2021;9:657875.
43. Hamani C, Pilitsis J, Rughani AI, Rosenow JM, Patil PG, Slavin KS, Abosch A, Eskandar E, Mitchell LS, Kalkanis S, American Society for S, Functional N. S. Congress of Neurological, Cns, S. American Association of Neurological, Deep brain stimulation for obsessive-compulsive disorder: systematic review and

- evidence-based guideline sponsored by the American Society for Stereotactic and Functional Neurosurgery and the Congress of neurological surgeons (CNS) and endorsed by the CNS and American Association of neurological surgeons, *Neurosurgery* 75(4) (2014) 327–33; quiz 333.
44. Sansur CA, Frysinger RC, Pouratian N, Fu KM, Bittl M, Oskouian RJ, Laws ER, Elias WJ. Incidence of symptomatic hemorrhage after stereotactic electrode placement. *J Neurosurg.* 2007;107(5):998–1003.
 45. Gonzalez-Martinez J, Mullin J, Vadera S, Bulacio J, Hughes G, Jones S, Enatsu R, Najm I. Stereotactic placement of depth electrodes in medically intractable epilepsy. *J Neurosurg.* 2014;120(3):639–44.
 46. Voroslakos M, Takeuchi Y, Brnyiczki K, Zombori T, Oliva A, Fernandez-Ruiz A, Kozak G, Kincses ZT, Ivanyi B, Buzsaki G, Berenyi A. Direct effects of transcranial electric stimulation on brain circuits in rats and humans. *Nat Commun.* 2018;9(1):483.
 47. Beliaeva V, Savvateev I, Zerbi V, Polania R. Toward integrative approaches to study the causal role of neural oscillations via transcranial electrical stimulation. *Nat Commun.* 2021;12(1):2243.
 48. Asan AS, Gok S, Sahin M. Electrical fields induced inside the rat brain with skin, skull, and dural placements of the current injection electrode. *PLoS ONE.* 2019;14(1):e0203727.
 49. Paxinos G, Keith BJ, Franklin. The mouse brain in stereotaxic coordinates: hard cover edition. Access Online via Elsevier; 2001.
 50. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. *J Cell Biol.* 2018;217(2):459–72.
 51. Nayak D, Roth TL, McGavern DB. Microglia development and function. *Annu Rev Immunol.* 2014;32:367–402.
 52. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010;140(6):918–34.
 53. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. *Prog Neurobiol.* 2005;76(2):77–98.
 54. Minghetti L. Role of inflammation in neurodegenerative diseases. *Curr Opin Neurol.* 2005;18(3):315–21.
 55. Yang CN, Shiao YJ, Shie FS, Guo BS, Chen PH, Cho CY, Chen YJ, Huang FL, Tsay HJ. Mechanism mediating oligomeric abeta clearance by naive primary microglia. *Neurobiol Dis.* 2011;42(3):221–30.
 56. Solito E, Sastre M. Microglia function in Alzheimer's disease. *Front Pharmacol.* 2012;3:14.
 57. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell.* 2013;155(7):1596–609.
 58. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. *Ann Transl Med.* 2015;3(10):136.
 59. Jaworski T, Lechat B, Demedts D, Gielis L, Devijver H, Borghgraef P, Duimel H, Verheyen F, Kugler S, Van Leuven F. Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. *Am J Pathol.* 2011;179(4):2001–15.
 60. Sparta B, Pargett M, Minguet M, Distor K, Bell G, Albeck JG. Receptor level mechanisms are required for epidermal growth factor (EGF)-stimulated Extracellular Signal-regulated kinase (ERK) activity pulses. *J Biol Chem.* 2015;290(41):24784–92.
 61. Albeck JG, Mills GB, Brugge JS. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. *Mol Cell.* 2013;49(2):249–61.
 62. Ryu H, Chung M, Dobrzynski M, Fey D, Blum Y, Lee SS, Peter M, Kholodenko BN, Jeon NL, Pertz O. Frequency modulation of ERK activation dynamics rewires cell fate. *Mol Syst Biol.* 2015;11(11):838.
 63. Toettcher JE, Weiner OD, Lim WA. Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module. *Cell.* 2013;155(6):1422–34.
 64. Wilson MZ, Ravindran PT, Lim WA, Toettcher JE. Tracing Information Flow from Erk to Target Gene Induction Reveals Mechanisms of Dynamic and Combinatorial Control. *Mol Cell* 67(5) (2017) 757–769 e5.
 65. Guo L, Li H, Wang Y, Li Z, Albeck J, Zhao M, Qing Q. Controlling ERK Activation Dynamics in Mammary epithelial cells with Alternating Electric Fields through Microelectrodes. *Nano Lett.* 2019;19(10):7526–33.
 66. Guo L, Zhu K, Pargett M, Contreras A, Tsai P, Qing Q, Losert W, Albeck J, Zhao M. Electrically synchronizing and modulating the dynamics of ERK activation to regulate cell fate. *iScience.* 2021;24(11):103240.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.